Shares of Kodiak Sciences surged 68.6% to their highest in more than four years on Thursday after the drug developer’s experimental drug met the main goal in a late-stage study in patients with diabetes-related eye damage.
Recent Posts
- WhiteFiber Stock Falls After Q4 Earnings Miss And Wider Loss
- Keymed Biosciences Announces 2025 Annual Results and Business Updates
- China’s ‘Africa Diaper King’ Delivers Strong Annual Profit Post-IPO
- CStone Announces 2025 Annual Results: Accelerated Expansion of Global Commercial Footprint and Efficient Advancement of Innovation Pipeline 2.0
- Can-Fite Reports 2025 Financial Results and Ongoing Clinical Progress Highlighting Positive Data in Phase 2a Pancreatic cancer and 9 Years Cancer-Free Survival in Liver Cancer Patient